Leading US medical experts advising the government voted against recommending booster doses of Pfizer's COVID-19 vaccine for everyone aged 16 and up, citing concerns about potential side-effects in younger age groups.
Following a day of data presentations and debate, the panel of vaccinologists, infectious disease researchers, and epidemiologists voted 16 to 2 against the measure, but left the door open to agreeing to a third shot for older people.
The decision represented a rebuke to President Joe Biden's administration, which had announced a plan to start rollout of booster shots this month before consulting its scientific agencies. The Food and Drug Administration struck a cautious tone in documents released ahead of Friday's meeting where an independent panel has been convened.
Peter Marks, a senior FDA scientist who opened the meeting, asked participants "to focus our deliberations on the science... and not on operational issues related to a booster campaign or on issues related to global vaccine equity."
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Pfizer says third COVID shot gives antibodies in threefold, likely can handle Delta variantThe FDA on Wednesday posted much of the evidence from Pfizer on booster shots to be considered by its advisory panel on Friday.
Lire la suite »
FDA Questions Need For Pfizer Covid-19 Booster Shot Ahead Of Vote FridayScientists at the FDA said Pfizer’s Covid-19 vaccine seems to last long enough that a booster shot may not add much protection
Lire la suite »
FDA Questions Need For Pfizer Covid-19 Booster Shot Ahead Of Vote FridayScientists at the FDA said Pfizer’s Covid-19 vaccine seems to last long enough that a booster shot may not add much protection
Lire la suite »
What to expect as FDA advisory panel debates Pfizer COVID booster shotsThe FDA's independent advisory committee is convening to review data submitted by Pfizer and discuss whether a booster dose is safe enough for widespread use and whether it's necessary and effective at improving protection levels against COVID-19.
Lire la suite »
FDA advisers vote to oppose Pfizer/BioNTech COVID-19 vaccine boosterA panel of outside advisers to the U.S. Food and Drug Administration on Friday voted against approval of a booster dose of the Pfizer Inc /BioNTech SE COVID-19 vaccine for people aged 16 and older.
Lire la suite »
How the U.S. Nailed the Economic Response to Covid-19The shutdown was initially the worst hit to the U.S. economy since the Great Depression, but the fiscal policy succeeded in pushing poverty in the opposite direction that usually occurs in recessions.
Lire la suite »